The company in question is, Novo Nordisk A/S (NYSE:NVO) currently with a stock price of 45.49 (-1.32% today). The market cap for Novo Nordisk A/S is 96249.42, and is in the sector Healthcare, and Drug Manufacturers – Other industry. The target price for Novo Nordisk A/S is 57. Currently Novo Nordisk A/S is trading with a P/E of 21.56, and a forward P/E of 18.85. Average volume for Novo Nordisk A/S is 2288.91 and so far today it is 523780.
Performance in the last year for Novo Nordisk A/S has been -16.83%. For EPS growth, Novo Nordisk A/S has seen a growth of 34.30%, and is looking to grow in the next year to 6.49%. More long term stats show that EPS growth has been 22.40% over the last five years and could be 10.90% for the next five years. Novo Nordisk A/S has seen sales growth quarter over quarter at 1.50%, with EPS growth quarter over quarter at 21.50%. The 20-day simple moving average is -10.13%, with the 200-day simple moving average coming to -13.99%.
Since the IPO date for Novo Nordisk A/S on the 1/4/1982, Novo Nordisk A/S has seen performance year to date to be -18.45%. With Novo Nordisk A/S trading at 45.49, the dividend yield is 3.06%, and the EPS is 2.14.
So could Novo Nordisk A/S, be undervalued? Well as said before P/E is 21.56. The PEG is 1.98, P/S is 5.77 and the P/B is at 18.15. The P/cash is 41.79, with P/free cash flow at 30.89.
Novo Nordisk A/S ability to deal with debt shows that the current ratio is 1.3, and the quick ratio is 0.9. This is with long term debt/equity at 0, and total debt/equity at 0.01.
In terms of margins, Novo Nordisk A/S has a gross margin of 84.80%, an operating margin of 43.40% and a profit margin of 32.70%.Payout ratio for Novo Nordisk A/S is 45.20%. Return on assets come to 41.50% with return on investment coming to 85.00%.
Insider ownership for Novo Nordisk A/S, is at 26.40% and institutional ownership comes to 10.00%. Outstanding shares are at 2087.84. While shares float is 1356.68. The float short is currently 0.15%, and short ratio is 0.89.